A protein microarray assay for serological determination of antigen-specific antibody responses following Clostridium difficile infection by Negm, Ola H. et al.
Negm, Ola H. and Hamed, Mohamed R. and Monaghan, 
Tanya M. (2018) A protein microarray assay for 
serological determination of antigen-specific antibody 
responses following Clostridium difficile infection. 
Journal of Visualized Experiments, 136 . e57399. ISSN 
1940-087X 
Access from the University of Nottingham repository: 
http://eprints.nottingham.ac.uk/49192/1/A%20Protein%20microarray%20assay%20for
%20serological%20determination%20of%20antigen-specific%20antibody%20responses
%20following%20Clostridium%20difficile%20infection%20-%20JoVE
%202017%20Monaghan.pdf
Copyright and reuse: 
The Nottingham ePrints service makes this work by researchers of the University of 
Nottingham available open access under the following conditions.
This article is made available under the University of Nottingham End User licence and may 
be reused according to the conditions of the licence.  For more details see: 
http://eprints.nottingham.ac.uk/end_user_agreement.pdf
A note on versions: 
The version presented here may differ from the published version or from the version of 
record. If you wish to cite this item you are advised to consult the publisher’s version. Please 
see the repository url above for details on accessing the published version and note that 
access may require a subscription.
For more information, please contact eprints@nottingham.ac.uk
          
TITLE:  1 
A Protein microarray assay for serological determination of antigen-specific antibody responses 2 
following Clostridium difficile infection 3 
 4 
AUTHORS & AFFILIATIONS:  5 
Ola H Negm1,2, Mohamed Hamed1,2, Tanya M Monaghan3 6 
1Breast Surgery Group, Division of Medical Sciences and Graduate Entry Medicine, School of 7 
Medicine, Queen’s Medical Centre, University of Nottingham, Nottingham, UK 8 
2Medical Microbiology and Immunology Department, Faculty of Medicine, Mansoura University, 9 
Egypt. 10 
3Nottingham Digestive Diseases Centre and NIHR Nottingham Digestive Diseases Biomedical 11 
Research Centre, School of Medicine, Queen’s Medical Centre, University of Nottingham, UK 12 
 13 
Corresponding authors:  14 
Dr Tanya M Monaghan and Dr Ola Negm 15 
Email addresses: Tanya.Monaghan@nottingham.ac.uk & Ola.Negm@nottingham.ac.uk 16 
 17 
EMAIL ADDRESSES: 18 
ola.negm@nottingham.ac.uk 19 
mrefaat.hamed@yahoo.com 20 
Tanya.Monaghan@nottingham.ac.uk 21 
 22 
KEYWORDS:  23 
Protein, microarray, antibody, Clostridium difficile, intravenous, immunoglobulin 24 
 25 
SHORT ABSTRACT:  26 
Here, we describe a simple protein microarray method for profiling humoral immune responses 27 
to a 7-plex panel of highly purified Clostridium difficile antigens in human sera. This protocol can 28 
be extended for the determination of specific antibody responses in preparations of polyclonal 29 
intravenous immunoglobulin (IVIg). 30 
 31 
LONG ABSTRACT:  32 
We provide a detailed overview of a novel high-throughput protein microarray assay for the 33 
determination of anti-C. difficile antibody levels in human sera and in separate preparations of 34 
polyclonal IVIg. The protocol describes the methodological steps involved in sample preparation, 35 
printing of arrays, assay procedure and data analysis. In addition, this protocol could be further 36 
developed to incorporate diverse clinical samples including plasma and cell culture supernatants. 37 
Herein, a combination of isotype (IgG, IgA IgM), subclass (IgG1, IgG2, IgG3, IgG4, IgA1, IgA2), and 38 
strain-specific antibodies to highly purified whole C. difficile toxins A and B (toxinotype 0, strain 39 
VPI 10463, ribotype 087), toxin B from a C. difficile toxin-B-only expressing strain (CCUG 20309), 40 
precursor form of B fragment of binary toxin, pCDTb, ribotype-specific whole surface layer 41 
proteins (SLPs; 001, 002, 027) and control proteins (Tetanus toxoid and Candida albicans) were 42 
determined by protein microarray. Microarrays were probed with sera from individuals with C. 43 
difficile infection (CDI), cystic fibrosis (CF) without diarrhea, healthy controls and individuals pre- 44 
 
  
 
 
and post-IVIg therapy for treatment of CDI, combined immunodeficiency disorder and chronic 45 
inflammatory demyelinating polyradiculopathy. Significant differences in toxin neutralization 46 
efficacies and multi-isotype specific antibody levels were seen between patient groups, 47 
commercial preparations of IVIg  and sera before and following IVIg administration. A significant 48 
correlation was observed between microarray and enzyme-linked immunosorbent assay (ELISA) 49 
for antitoxin IgG levels in serum samples. These results suggest that microarray could become a 50 
promising tool for profiling antibody responses to C. difficile antigens in vaccinated or infected 51 
humans. With further refinement of antigen panels and a reduction in production costs, it is 52 
anticipated that microarray technology may help optimize and select the most clinically useful 53 
immunotherapies for C. difficile infection in a patient-specific manner.  54 
 55 
INTRODUCTION:   56 
In this protocol, we describe the development and validation of a novel and customized protein 57 
microarray assay for detection and semi-quantification of bacterial strain and isotype-specific 58 
antibody responses to C. difficile antigens. We have successfully used our C. difficile-specific 59 
microarray assay as a promising new tool for compositional bioanalysis of specific antibody 60 
content in patient sera1,2, preparations of IVIg 3 and to identify antibody specificities that 61 
correlate with poor outcomes in CDI4. We demonstrate how biobanked serum samples and 62 
commercial preparations of IVIg can be analysed on microarray slides, allowing high-quality 63 
reproducible profiling of C. difficile pathogen-specific antibody responses in this assay. 64 
 65 
Many healthy children and adults have detectable serum IgG and IgA antibodies to C. difficile 66 
toxins A and B5,6. These are thought to arise following transient exposure during infancy and 67 
following exposure to C. difficile in adulthood. For this reason, polyclonal IVIg has been used off-68 
label to treat both recurrent and fulminant CDI7-9. However, its definitive role and mode of action 69 
remains unclear. Several studies have shown that the humoral immune response to C. difficile 70 
toxins plays a role in disease presentation and outcome. Specifically, asymptomatic patients 71 
show increased serum anti-toxin A IgG concentration compared to patients who develop 72 
symptomatic disease10. A demonstrable association has been reported for median anti-toxin A 73 
IgG titers and 30-day all-cause mortality11. Several reports have also revealed an association with 74 
protection against recurrence and antibody responses to toxin A, B, and several non-toxin 75 
antigens [Cwp66, Cwp84, FliC, FliD, and SLPs]12-15. These observations have spurred the 76 
development of the first passive immunotherapy drug targeting C. difficile toxin B 77 
(Bezlotuxumab), which has recently been approved by the US Food and Drug Administration and 78 
the European Medicines Agency for prevention of recurrent CDI16. Vaccination strategies using 79 
inactivated toxins or recombinant toxin fragments are also currently under development17-19. 80 
These new therapeutic approaches will undoubtedly stimulate the requirement for evaluating 81 
humoral immune responses to multiple antigens in large sample sizes. 82 
 83 
Today, there is a notable lack of commercially available high-throughput assays capable of 84 
simultaneously assessing bacterial strain and isotype-specific antibody responses to C. difficile 85 
antigens. There is an unmet need to develop such assays to facilitate future research efforts and 86 
clinical applications. Protein microarrays are a method to immobilize large numbers of 87 
individually-purified proteins as a spatially organized array of spots onto a microscopic slide-88 
 
  
 
 
based surface by using a robotic system, which can be either a contact 20or a non-contact printing 89 
tool21. The spots may represent complex mixtures such as cell lysates, antibodies, tissue 90 
homogenates, endogenous or recombinant proteins or peptides, body fluids or drugs22,23.  91 
 92 
Protein microarray technology offers distinct advantages over standard in-house ELISA 93 
techniques, which have traditionally been used to assess anti-C. difficile antibody responses. 94 
These include an increased capacity for detecting a range of multi-isotype-specific antibodies 95 
against a more extensive panel of protein targets, reduced volume requirements for antigens, 96 
samples and reagents, an enhanced ability to incorporate a larger number of technical replicates, 97 
in addition to multiple internal quality control (QC) measures1. Microarrays are therefore more 98 
sensitive, accurate and reproducible and have a greater dynamic range. These factors make 99 
microarrays a cheaper and potentially favorable alternative to ELISAs for the large-scale 100 
detection of known proteins. However, disadvantages of microarray technology result mainly 101 
from the large up-front costs associated with establishing a panel of highly purified antigens and 102 
setting up the technological platform. 103 
 104 
Protein microarrays have been extensively used over the past two decades as a diagnostic and 105 
basic research tool in clinical applications. Specific applications include protein expression 106 
profiling, the study of enzyme-substrate relationships, biomarker screening, analysis of host-107 
microbe interactions, and profiling antibody specificity23-28. Many new pathogen protein/antigen 108 
microarrays have been established, including malaria (Plasmodium)29, HIV-130, influenza31, 109 
severe acute respiratory syndrome (SARS)32, viral hemorrhagic fever33, herpes-viruses34, and 110 
tuberculosis35.  111 
 112 
The present protocol relates to the establishment of an easy operating C. difficile reactive antigen 113 
microarray assay, which enables accurate, precise and specific quantification of multi-isotype and 114 
strain-specific antibody responses to C. difficile antigens in sera and polyclonal IVIg. Herein, we 115 
include representative results pertaining to acceptable microarray assay performance when 116 
compared to ELISA as well as assay precision and reproducibility profiles. This assay could be 117 
further developed to profile other clinical samples and sets a new standard for research into the 118 
molecular basis of CDI. 119 
 120 
PROTOCOL:  121 
 122 
1. Preparing microarray plate 123 
 124 
1.1. Dilute C. difficile antigens in printing buffer [PBS-Tween-Trehalose (50mM)] at the optimum 125 
concentration (which was predefined before running the patient sera); toxin A (200 μg/mL) and 126 
toxin B (100 μg/mL), pCDTb (200 μg/mL) and purified native whole SLPs derived from ribotypes 127 
001, 002 and 027 (200 μg/mL).  128 
 129 
Note: Toxin B was obtained from toxin B-expressing strain CCUG 20309 (90 μg/mL). 130 
 131 
1.1.1. Dilute the positive controls, lysates of Candida albicans and Tetanus toxoid in printing 132 
 
  
 
 
buffer at 100 μg/mL. Finally, dilute purified human immunoglobulin matching the tested antibody 133 
isotype serially starting at 50 μg/mL across 10 dilutions in the printing buffer to create a 134 
calibration curve. 135 
 136 
1.2. Transfer 10 μL of the dilutions in the printing buffer into a 384 well plate.  137 
 138 
1.3. Cover the plate with a plate seal and centrifuge at 300 x g for 5 min. 139 
 140 
2. Printing of Arrays with a non-contact robot 141 
 142 
2.1. Heat the silicon pin using the hand-held gas burner three times, 2 s each and rinse in clean 143 
water three times, 3 s each. 144 
 145 
2.2. Place the microarray plate into the BioBank (loading cartridge) of the arrayer. Set up the 146 
humidity level of the arrayer to a level ranging from 55-60%. 147 
 148 
2.3. Place the aminosilane slides on the slide tray.  149 
 150 
Note: The slide tray can hold 27 slides: three rows of 9. The slides are arranged in portrait 151 
orientation starting from the left side of the bottom row and the rest of the spaces are covered 152 
with blank slides to ensure that all holes on the slide tray are covered.  153 
 154 
2.3.1. Press OK and check that a vacuum has been created and all the slides are secure. Leave the 155 
slides in the humid environment for at least 1 h before starting the print.  156 
 157 
Note: The aminosilane slides are provided in a sealed pouch with desiccant. Once opened, any 158 
unused slides should be returned immediately to the desiccator for storage up to the expiry date. 159 
 160 
2.4. Print each sample in quadruplicates in 16 identical subarray formats. Launch the TAS 161 
Application Suite and open the required print run parameters file from the 'My Gridding Runs' 162 
directory. Upon double-clicking on the MicroArray icon on the main window a three-tabbed 163 
window will appear called ‘MicroArraying parameters [untitled]’.  The three tabs are “Source”, 164 
“Target” and “Options”. The “Source” tab shows details of how the samples are stored on the 165 
plates. The “Target” tab shows details of how the slides are to be loaded, where the array should 166 
be printed on the slide and edit the slide layout (16 subarray formats). The “Options” tab shows 167 
details of the wash protocol and tool to be used e.g. wash after every completed sample. Do not 168 
start the run until the target humidity has been reached, otherwise the spots will be the wrong 169 
size and the library will rapidly evaporate. Start the run and periodically observe the arrayer 170 
during the print run to be certain everything is OK.  171 
 172 
Note: This enables the analysis of 15 samples in parallel on each slide as one subarray is used as 173 
a negative control. The design of subarrays is determined by the number of the printed proteins 174 
(antigens) and the number of the printed biological replicates.   175 
 176 
 
  
 
 
2.5. Clean the silicon pin between samples to avoid any cross contamination between different 177 
samples.  The programming options are located under Window>Run Preferences on the TAS 178 
Application Suite toolbar. There are 9 tabs to work through in this section and as you complete 179 
one tab move to the next by clicking on it. Clicking the “OK” the button will take you out of “Run 180 
Preferences”. In the “General” tab of the “Run preferences”, there are a number of check boxes 181 
available under this section relating to how the instrument will behave when a program is started. 182 
Check the “Load BioBank” box, at the start of a run the user will be prompted to load the BioBank 183 
and conversely will be prompted to unload the BioBank at the end of the run. Check the “Prime 184 
bath before start of run” box, all three wash stations will undergo a short priming sequence prior 185 
to the run beginning. Check the “Wash at start of run” box, the pin tool will be washed before 186 
the first source visit. Check “Wash at end of run” box, the pin tool will be washed after the last 187 
source visit. The user can set the number of wash cycles. 188 
 189 
Note: After printing each sample, the head moves toward the washing baths to allow multiple 190 
dipping of the pin into two wash baths containing distilled water and 0.002% Tween 20 for 1.5 s 191 
in each bath, followed by rinsing the pin with ultra-pure water and drying the pin in the main 192 
wash station for 4 s. 193 
 194 
3. Storage of the Arrays 195 
 196 
3.1. Keep the printed slides stored in the desiccator overnight at room temperature. 197 
 198 
Note: The printed slides can be stored for up to 1 week. 199 
 200 
4. Array Probing 201 
 202 
4.1. Carefully place printed slides in a 16 multi-well chambers format slide holder.  203 
 204 
Note: Chambers having a depth of approximately 7.5 mm provide a generous surface to volume 205 
ratio to facilitate mixing and washing steps. 206 
 207 
4.2. Allow all reagents to warm to room temperature before use. Unless specified otherwise, 208 
perform all the following steps at room temperature. 209 
 210 
4.3. Add 100 μL of filtered 5% bovine serum albumin (BSA; use 0.2 μm syringe filter) to each 211 
block, cover the slides and incubate with shaking for 1 h. 212 
 213 
4.4. Wash the slides 5 times, 1 min each with 120 μL PBST (0.1% Tween) per well with shaking. 214 
Do not let the slides dry out. 215 
 216 
4.5. Thaw serum samples on ice for 20 minutes and dilute each sample in a commercial available 217 
antibody diluent with background reducing component (see table of materials).  218 
 219 
4.5.1. Optimize the dilution of the serum samples according to the tested immunoglobulin as 220 
 
  
 
 
shown in Table 2. 221 
 222 
4.6. Transfer 100 μL of the diluted serum samples to all blocks except one block which will be 223 
used as a negative control; to this add 100 μL of antibody diluent only. Incubate the slides with 224 
gentle agitation for 1 h. 225 
 226 
4.7. Wash the slides 5 times, 3 min each with 120 μL PBST (0.1% Tween) per well, with shaking. 227 
 228 
4.8. Add 100 μL biotinylated goat anti-human antibody diluted in antibody diluent.  229 
 230 
4.8.1. Optimize the dilution of the secondary antibody according to the tested immunoglobulin 231 
as described in Table 2. Cover the slides and incubate with gentle shaking for 1 h. 232 
 233 
4.9. Wash the slides 5 times, 3 min each with 120 μL PBST per well with shaking. 234 
 235 
4.10. Add 100 μL streptavidin Cy5 to each block diluted at 1:2000 in 5% BSA. Cover the slides with 236 
foil to protect from light whilst shaking for 15 min with gentle agitation. 237 
 238 
4.11. Wash the slides 5 times, 1 min each with 120 μL PBST per well with shaking, followed by a 239 
further 2 washes, 1 min each with PBS only with shaking. 240 
 241 
4.12. Spin the slides for 5 min at 300 x g to dry them. 242 
 243 
4.13. Keep the slides in a dark box for transport and storage at room temperature. 244 
 245 
4.14. Proceed to scan the arrays immediately to ensure signal consistency after probing.  246 
 247 
Note: However, probed slides can be stored in the dark and scanned within one week from 248 
probing. 249 
 250 
5. Scanning the arrays 251 
 252 
5.1. Switch on the laser scanner (see table of materials) 30 min to warm up the laser before 253 
scanning. Load up the scanner software and connect the computer to the scanner. 254 
 255 
5.2. Place a slide with the printed side face up into the scanner until the play light turns solid 256 
green. 257 
 258 
5.3. Press the settings button and adjust the following settings when scanning the slides as 259 
follows; Scan mode: median, Acquisition: 635 Only, Acquisition mode: Manual, Gain: 20, Power: 260 
Low, Slide type: Unlabeled Slide, Focus: Auto Focus, Automatic Scrolling, Automatic Scrolling: 261 
off, Barcode Reading, Pixel Size: 10, Scan:35 262 
 263 
5.4. Save the resultant images as 16-bit grey scale multiple image Tiff format. Press the import 264 
 
  
 
 
grid button and select the appropriate array list.   265 
 266 
Note: Array list describes the size and position of subarrays and the names of the printed 267 
substances associated with each feature-indicator.  268 
 269 
5.4.1. Align the grid to the spots on the slide. 270 
 271 
5.5. Analyse the images by pressing the photometric calculation button to measure the 272 
fluorescence signal intensities of each spot and save the results (in a text format called GenePix 273 
Results (GPR) file).  274 
 275 
Note: The GPR file contains the localization and identification variables of the antigen targets on 276 
the array, and also the median fluorescence intensity and the local background that represents 277 
the antibody binding signal values of each spot.   278 
  279 
6. Data analysis  280 
 281 
6.1. Calculate the median for the replicates of each antigen after background subtraction using a 282 
free microarray analysis software called reverse phase microarray (RPPA) analyser, a module 283 
within the R statistical language on CRAN36.   284 
 285 
6.2. Plot the standard curve and interpolate the signals of each antigen relative to the 286 
immunoglobulin standard curve using commercial scientific graphing and statistics software (see 287 
table of materials) to calculate the antibody levels. 288 
 289 
REPRESENTATIVE RESULTS:   290 
Figure 1 illustrates a flowchart describing the major steps in the described protocol. Figure 2 291 
shows Spearman correlation tests demonstrating significant agreement between microarray and 292 
ELISA for IgG and IgA anti-toxin A and B levels in patient test sera. Figure 3 shows differential IgG 293 
and IgA antibody-class specific antibody responses to toxins A, B and binary toxin (pCDTb) in 294 
patients with CF without diarrhea, CDI patients with diarrhea and HC. Figure 4 shows C. difficile 295 
antitoxin neutralizing antibody responses in patient sera. Figure 5 shows immune reactivity 296 
(against C. difficile toxins and SLPs) and neutralizing effect (against C. difficile toxins) of IVIg. 297 
Figure 6 shows immune reactivity (against C. difficile toxins and SLPs) and neutralizing effect 298 
(against C. difficile toxins) of patient sera pre- and post IVIg administration. Table 1 shows 299 
acceptable intra- and inter-assay coefficients of variability of microarray using test sera. Table 2 300 
illustrates a list of immunoglobulins used in this study with relevant concentrations of purified 301 
proteins as well as optimized dilutions for sera and secondary antibodies. 302 
 303 
FIGURE AND TABLE LEGENDS: 304 
 305 
Figure 1: General overview of the major steps involved in the microarray protocol. These begin 306 
with preparation of antigens and controls. Subsequent sample dilutions are transferred to a 384-307 
plate in readiness for printing in quadruplicates onto aminosilane slides. Following drying and 308 
 
  
 
 
blocking of slides, the arrays are incubated with patient sera. After further washing, biotinylated 309 
anti-human Ig of the specified isotype is added. After final washing and drying steps, the slides 310 
are scanned and the resultant images processed with microarray image analysis software. 311 
 312 
Figure 2: Correlation between microarray and ELISA results. The Spearman correlation co-313 
efficient was used to assess the level of agreement between the two platforms. When comparing 314 
microarray performance with in-house ELISA, (A) a good correlation coefficient was observed for 315 
toxin A (r = 0.7051; P <0.0001), (B) with a moderately good correlation for toxin B (r=0.5809; P 316 
<0.0001). The full ELISA protocol has been detailed elsewhere37. Abbreviations: ELISA, enzyme-317 
linked immunosorbent assay. This figure has been reprinted from Negm et al.1 with permission.  318 
 319 
Figure 3: Isotype-specific antibody responses to C. difficile toxins. Serum anti-toxin IgG and IgA  320 
responses (toxinotype 0, strain VPI 10463, ribotype 087; toxin A at 200 μg/mL, toxin B at 100 321 
μg/mL), toxin B (C. difficile toxin B-producing strain CCUG 20309; toxin B at 90 μg/mL) and 322 
precursor form of B fragment of binary toxin, pCDTb (200 μg/mL), in patients with CF without 323 
diarrhea, CDI with diarrhea and HC. Serum dilution for IgG and IgA 1:500 and 1:100 respectively. 324 
Differences between groups were assessed using the Kruskall-Wallis test followed by Dunn’s post 325 
hoc test for multiple responses. Compared with HC (n=17) and patients with symptomatic CDI 326 
(n=16), adult CF patients (n=16) exhibited significantly higher levels of serum IgA anti-toxin A and 327 
=B levels; p ≤0.05. The same pattern prevailed for IgG, except that there was no difference in 328 
anti-toxin A IgG levels between the groups. Box and whisker plots represent median, range and 329 
quartiles. *** p≤0.0001; ** p≤0.01; *p≤0.05. Standardized signals are normalized to 330 
immunoglobulin standard curve. Abbreviations: C. difficile, Clostridium difficile; CDI, C. difficile 331 
infection; CF, cystic fibrosis; HC, healthy controls; Ig, immunoglobulin. This figure has been 332 
reprinted from Monaghan et al.2, with permission. 333 
 334 
Figure 4: Neutralizing antibody (NAb) efficacies to C. difficile toxins A and B in patients’ sera.  335 
Protective NAb responses to C. difficile toxins A and B (toxinotype 0, strain VPI 10463, ribotype 336 
087, used at LD50) in sera (1:100 dilution; toxin A 2.5 ng/mL, toxin B 0.5 ng/mL) from HC, patients 337 
with CF without diarrhea, and CDI with diarrhea. Sera from CF patients exhibited significantly 338 
stronger protective anti-toxin NAb responses compared with HC (toxins A and B) and patients 339 
with CDI (toxin A). Differences between groups were assessed using Kruskall-Wallis test followed 340 
by Dunn’s post hoc test for multiple responses. Box and whisker plots represent the median, 341 
range and quartiles. **p≤0.01; *p≤0.05. Abbreviations: C. difficile, Clostridium difficile; CDI, C. 342 
difficile infection; CF, cystic fibrosis; HC, healthy controls; LD50, 50% lethal dose. This figure has 343 
been reprinted from Monaghan et al. 2, with permission. 344 
 345 
Figure 5: Immune reactivity and neutralizing effect of IVIg to Clostridium difficile antigens. (A) 346 
Reactivity of multi-isotype specific antibodies to C. difficile antigens in commercial IVIg 347 
preparations: heat map illustrates the levels of specific antibody isotypes (IgG, IgG1, IgG2, IgG3, 348 
IgG4, IgA, IgA1, IgA2 and IgM) in three commercially available preparations (see table of 349 
materials) against seven C. difficile antigens [toxin A (200 μg/mL, toxin B (100 μg/mL), pCDTb (200 350 
μg/mL) toxin B (CCUG 20309; 90 μg/mL) and SLPs 001, 002 and 027; all 200 μg/mL] using protein 351 
microarray technology. Color code of the heat-map: green (low) to red (high) signal intensity. 352 
 
  
 
 
Signal values represented on the color scale for the heat-map are log2-transformed from the 353 
arbitrary fluorescence units (AFU). Please note AFU has more recently been superseded by the 354 
descriptor standardized signals2. Total IgG, IgG1 and IgG2 isotypes gave the highest binding 355 
reactivities against toxin A, toxin b, binary toxin (pCDTb) and toxin B (CCUG 20309). (B) IVIg 356 
neutralization efficacy against C. difficile native whole toxins A and B: percentage of protective 357 
neutralization effect of commercial IVIg products against C. difficile toxins A and B. Each plot 358 
represents the median of triplicate experiments at 1:100 dilution. IVIg preparation 1 exhibits the 359 
lowest protective effect compared to IVIg preparations 2 and 3, particularly against toxin A. P-360 
values of ****≤0.0001; *≤0.05 (one-way analysis of variance). Abbreviations: IVIg, intravenous 361 
immunoglobulin; AFU, arbitrary fluorescence units; pCDTb, precursor form of B fragment of 362 
binary toxin, pCDTb; SLPs, surface layer proteins. This figure has been modified from Negm et 363 
al.3, with permission. 364 
 365 
Figure 6: Immune reactivity and neutralizing effect of patient’s sera to Clostridium difficile 366 
antigens. (A) Comparison of antibody reactivities against C. difficile proteins in patients’ sera 367 
before and after IVIg infusion: heat-map illustrates the expression level of the isotypes (IgG, IgG1, 368 
IgG2, IgG3, IgG4, IgA, IgA1, IgA2 and IgM) in serum samples in seven patients before and after 369 
IVIg infusion against seven C. difficile antigens [toxin A (200 μg/mL, toxin B (100 μg/mL), pCDTb 370 
(200 μg/mL) toxin B (CCUG 20309; 90 μg/mL) and SLPs 001, 002 and 027; all 200 μg/mL] using 371 
protein microarray technology. Color code of the heat-map: green (low) to red (high) signal 372 
intensity. Signal values represented on the color scale for the heat-map are log2-transformed 373 
from the arbitrary fluorescence units (AFU). Please note AFU has more recently been superseded 374 
by standardized signals2. There was post-infusion enhancement of the total IgG, IgG1, IgG2 and 375 
IgG3 reactivities to toxin A, toxin B, and pCDTb. (B) IgG responses to toxins A, B and binary toxin 376 
(pCDTb) pre-and post-IVIg administration. Total IgG levels against all toxins show significant 377 
increase following IVIg administration (Wilcoxon’s signed-rank test). Each plot represents the 378 
median of triplicate experiments at 1:10 dilution. (C) neutralization effect against C. difficile 379 
native toxins A and B following IVIg administration: comparison of pre- and post-infusion 380 
neutralizing antibody activities showed enhanced protective effect after IVIg infusions against C. 381 
difficile native toxins (toxins A and B). Each plot represents the median of triplicate experiments 382 
at 1:10 dilution. A significant increase in the protective effect against toxins A and B was noted in 383 
patient sera tested post-IVIg infusion (Wilcoxon’s signed-rank test). Abbreviations: IVIg, 384 
intravenous immunoglobulin; AFU, arbitrary fluorescence units; pCDTb, precursor form of B 385 
fragment of binary toxin, pCDTb; SLPs, surface layer proteins. This figure has been reprinted from 386 
Negm et al.3, with permission. 387 
 388 
Table 1: Microarray intra-assay and inter-assay precision1. Microarray intra- and inter-assay 389 
variabilities were calculated using the sera of 7 patients. Identical samples were assayed on each 390 
of 2 slides at 2 independent time points. All antigens (n=7 test and n=2 controls) were spotted in 391 
replicates of 5 on each array.  392 
 393 
Table 2: List of immunoglobulins used in this study are shown with relevant purified protein 394 
concentrations (µg/mL), and dilutions for serum and secondary antibodies.  395 
 396 
 
  
 
 
DISCUSSION:  397 
In this protocol, we have shown that microarray is a suitable platform for defining humoral 398 
immune responses to C. difficile protein antigens in patient sera (Figures 3 and 6) and commercial 399 
preparations of IVIg (Figure 5). We have also demonstrated that the microarray technique 400 
performs well when compared to conventional ELISA (Figure 2) and shows excellent 401 
reproducibility, with intra- and inter-assay variabilities falling within acceptable limits of precision 402 
(Table 1). 403 
 404 
Critical steps: 405 
A number of critical steps must be followed when building any successful antigen microarray 406 
platform. Initially, it is extremely important to run QC experiments. In the QC experiment, 407 
different parameters should be evaluated such as selection of the appropriate surface chemistry, 408 
printing buffers, blocking buffers, dilutions of the serum samples and the secondary antibodies. 409 
These experiments must be performed with the aim of delivering a well-validated and reliable 410 
technique38-39. 411 
 412 
Selection of a suitable protein immobilisation process is one of the most important steps in 413 
microarray analyses, to ensure high-quality performance of the tested aminosilane slides, as seen 414 
in this study. It is crucial to observe regular and circular spot morphology, high and specific signal 415 
intensity and clear background.  Another factor affecting microarray performance is the printing 416 
buffer, which is equally important to achieve the desired surface chemistry to produce uniform 417 
and regular spots on the slide.  418 
 419 
It is important to select the correct settings for printing as this will allow the optimal size and 420 
shape of a spot to be printed. For example, the humidity level should be maintained around 55% 421 
during printing. This is because without humidity the rate of evaporation in the microarray 422 
chamber is increased and hence fewer spots are printed. 423 
 424 
Non-specific protein binding is an additional factor affecting the background and spot signals; 425 
therefore, appropriate selection of a blocking buffer could reduce any non-specific binding, 426 
leading to improved sensitivity and accuracy of the array data39.  427 
 428 
Modifications and troubleshooting: 429 
Antigens and serum samples must be aliquoted and stored into smaller storage tubes in the 430 
freezer until use, which helps avoid repeated multiple freeze-thaw cycles, which can deteriorate 431 
the signal strength of the array. To enhance the chances of a successful experiment, all the 432 
reagents must be prepared fresh and filtered. Cleaning the arrayer before printing and checking 433 
the settings are required. Moreover, the slide holder must be kept clean to minimize background 434 
noise. 435 
 436 
Limitations: 437 
The application of protein microarrays is currently hampered by the stringent demand on surface 438 
chemistry in protein microarray fabrication. Here the great variation in the chemical and physical 439 
properties of protein molecules necessitates custom-designing unique surface chemistry for 440 
 
  
 
 
different classes of protein and antibody molecules40. Other technical challenges facing the 441 
widespread implementation of such technology include the need for expensive specialized 442 
equipment and software with allocated bench-space, as well as consideration of maintenance 443 
charges, complex data analysis, relative protein quantification, and critically access to purified 444 
antigens.  445 
 446 
Significance of method with respect to existing/alternative methods: 447 
Microarray technology is similar in principle to ELISA, Meso Scale Discovery or Luminex 448 
immunoassays but customizable, can be scaled up to achieve statistical power, relies on only 449 
microliter quantities of precious samples, and has the ability to screen sera for multiple protein 450 
reactivities. It is therefore particularly suitable for large-scale, historical serum banks, biomarker 451 
discovery and screening. 452 
 453 
Future applications or directions of method: 454 
Future efforts will be directed towards optimizing the assay for other samples (cell supernatants), 455 
using the assay as a prognostic tool for patient stratification, externally validating potential 456 
biomarkers using large cohorts in a double-blind fashion, and predicting and optimizing response 457 
to immunotherapy (mAb, vaccines). In future, the microarray technology could be used in a 458 
hospital setting as a useful diagnostic tool or to monitor a drug treatment plan over a period of 459 
time. 460 
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